Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE Date: 28.03.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR"), we wish to inform you that the Board of Directors in their meeting held on 28th March, 2025 have considered and inter alia approved the following:

1. Investment of upto Euro 4,00,000 in the equity shares of SIA ZIM Laboratories Limited, Wholly owned Subsidiary of the Company.

2. Investment of upto AED 4,66,000 in the share capital of ZIM Scientific Office L.L.C., Step-down Subsidiary of the Company by ZIM Laboratories Limited FZE, Wholly Owned Subsidiary of the Company.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023, are also enclosed as Annexure I & II.

Kindly take the intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

PIYUSH SIDDHESHWAR NIKHADE

Digitally signed by PIYUSH SIDDHESHWAR NIKHADE
DN: c=IN, postalCode=440012, st=MAHARASHTRA, street=325 MAHALAXMI APPT NAGPURDHANTOLIWEST CENTREL ROAD 440012, l=NAGPUR, o=Personal, title=3526, serialNumber=3cced6ca26d23668ee558b723602e5236d527adc99269a3746951cdb919fca04, pseudonym=352620221206180703459, 2.5.4.20=42e9b6a98356f9095ec25716fc30d8cb8463fc1dc23adada5293c43849baaf78, email=CSPIYUSHNIKHADE@GMAIL.COM, cn=PIYUSH SIDDHESHWAR NIKHADE
Date: 2025.03.28 17:34:22 +05'30'

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Zeal & Innovation in Medicine

Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015:

Annexure I

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: SIA ZIM Laboratories Limited. The Company was incorporated in September, 2019. Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	Subscription to shares of SIA ZIM Laboratories Limited is not a related party transaction, however, SIA ZIM Laboratories Limited is a wholly owned subsidiary of the Company and is categorised as a Related Party of the Company. Mr. Zulfiquar Kamal, one of the Promoters of the Company is appointed as Director on the Board of SIA ZIM Laboratories Limited.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment in equity shares of SIA ZIM Laboratories Limited is with an objective of expansion and development of business in the European region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

Zeal & Innovation in Medicine

7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	Company will invest upto Euro 4,00,000 for acquisition of equity shares of SIA ZIM Laboratories Limited.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the Company's shareholding in SIA ZIM Laboratories Limited remains at 100%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SIA ZIM Laboratories Limited was incorporated in Latvia, Europe in September, 2019 to operate in Pharmaceutical Industry and is yet to commence its business operations.

Annexure II

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIM Scientific Office L.L.C. The Company was incorporated in November 2024. Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	The transaction of investment in share capital of ZIM Scientific Office L.L.C, Step-down Subsidiary of the Company by ZIM Laboratories FZE, Wholly Owned Subsidiary of the Company is a related party transaction and is at arms length. Mr. Zulfiquar Kamal, one of the Promoters of the Company is appointed as Directors on the Board of ZIM Scientific Office L.L.C.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment in share capital of ZIM Scientific Office L.L.C, Step-down Subsidiary is with an objective of expansion and development of business in the GCC region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	ZIM Laboratories FZE, Wholly Owned Subsidiary of the Company will invest upto AED 4,66,000 in the share capital of ZIM Scientific Office L.L.C, Step-down Subsidiary.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the shareholding of ZIM Laboratories FZE, Wholly Owned Subsidiary in ZIM Scientific Office L.L.C, Step-down Subsidiary remains at 100%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	ZIM Scientific Office L.L.C, Step-down Subsidiary was incorporated in Dubai, UAE in November, 2024 to operate in Pharmaceutical Industry and is yet to commence its business operations.